Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Monday, May 7, 2018

Enalapril plus folic acid reduces risk for first stroke in certain patients with hypertension

For your doctor to address with you.
Among patients with hypertension, those with high total homocysteine and low platelet count showed an elevated risk for first stroke, which was reduced when folic acid was added to enalapril treatment, according to a study published in the Journal of the American College of Cardiology.
“If confirmed, these results have enormous public health implications given the high incident rate of stroke in many developing countries, in addition to China,” Yong Huo, MD, director of the Heart Center of Peking University First Hospital in Beijing, said in a press release. “Based on our findings, we can detect hypertensive adults at particular high risk of stroke and incorporate a folic acid supplement tailored to individual genetic, nutritional and clinical characteristics. We are on the right path to figuring out cost-effective primary prevention strategies for stroke in China and beyond.”

Hypertension in China
Xiangyi Kong, MD, of the department of cardiology at Peking University First Hospital, and colleagues analyzed data from 10,789 patients (mean age, 60 years; 38% men) with hypertension from the China Stroke Primary Prevention Trial. Those with a history of physician-diagnosed MI, stroke, post-coronary revascularization, HF or congenital heart disease were excluded.
Patients were assigned 10 mg enalapril and 0.8 mg folic acid once per day (n = 5,408) or 10 mg enalapril only once per day (n = 5,381). During the trial, patients were allowed to use other antihypertensive drugs except B vitamins. Follow-up was conducted every 3 months.
Blood samples were collected at baseline to measure fasting lipids, fasting glucose, creatinine, serum total homocysteine, serum folate and vitamin B12.
The primary outcome was first fatal or nonfatal stroke. Patients were followed up for a median of 4.2 years.
During follow-up, 161 first strokes occurred in the enalapril-folic acid group vs. 210 in the enalapril-only group.
Patients with high platelet counts and low total homocysteine had the lowest incidence rate of first stroke (3.3%), and the highest incidence rate (5.6%) was seen in patients with low platelet counts and high total homocysteine.
Stroke risk reduction
Folic acid treatment reduced the risk for first stroke by 73% (HR = 0.27; 95% CI, 0.11-0.64) in patients with high total homocysteine and low platelet counts. Risk reduction in other subgroups was modest or nonsignificant.
“Our data suggest that identifying those patients with a combination of low [platelet count] and high [total homocysteine] (both biomarkers are easy to obtain) could help detect those individuals who are at high risk of stroke and who would particularly benefit from folic acid supplementation, a treatment that is simple, safe and inexpensive,” Kong and colleagues wrote. 

More at link.

No comments:

Post a Comment